Solventum Corporation Stock Price, News & Analysis

Solventum (NYSE: SOLV) has launched the Attest™ eBowie-Dick Test System, an innovative electronic sterilization testing solution that provides instant digital results and automated documentation. The system delivers definitive pass/fail results in under five seconds and integrates with hospital instrument tracking systems.

The new technology replaces traditional color-changing ink indicators used in steam dynamic-air removal sterilizers, reducing paper waste by 94% compared to conventional Bowie-Dick Test Packs. The system is now available in the United States through authorized distributors, with global rollout planned throughout 2025.

According to Chris Barry, executive vice president and group president of Medical Surgical at Solventum, the eBowie-Dick System revolutionizes sterilization testing by reducing processing times, eliminating result variability, and providing advanced analytics capabilities.

Solventum (NYSE: SOLV) reported Q4 2024 financial results with reported sales increasing 1.9% to $2.074 billion and organic sales growth of 2.3%. The company posted GAAP diluted EPS of $0.17 and adjusted EPS of $1.41, while generating $219 million in cash from operations and $92 million in free cash flow.

Growth was driven primarily by the MedSurg and Dental Solutions segments, though operating margins declined due to lower gross margins and increased operating expenses related to public company stand-up costs.

For 2025 guidance, Solventum projects:

• Organic sales growth of 1.0% to 2.0% (+1.5% to 2.5% excluding SKU Exit impact)
• Adjusted EPS of $5.45 to $5.65
• Free cash flow of $450M to $550M

Solventum (NYSE: SOLV) has announced plans to host an important Investor Day event on Thursday, March 20, 2025, in New York City. The event, scheduled to begin at 1:00 p.m. Eastern Standard Time, will provide insights into the company's long-term growth strategy.

The presentation will be accessible both in-person and through a virtual webcast format. Interested participants can find registration details and additional information at the company's investor relations website: https://investors.solventum.com. A replay of the webcast will be made available shortly after the conclusion of the live event.

Solventum (NYSE: SOLV) has announced the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. (NYSE: TMO) for $4.1 billion. This strategic divestiture is part of phase three of Solventum's transformation plan, aimed at sharpening focus on strategic growth areas and delivering long-term shareholder value.

The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing conditions. Solventum anticipates $3.4 billion in net proceeds, which will be primarily used to pay down debt, strengthening its balance sheet and reducing leverage.

According to CEO Bryan Hanson, this move will enhance Solventum's strategic focus and key metrics while enabling investment in innovation, programs, and talent. The company will discuss the transaction during its upcoming Q4 and full-year 2024 earnings call on February 27, 2025, with an Investor Day scheduled for March 20, 2025.

Thermo Fisher Scientific (NYSE: TMO) has announced a definitive agreement to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. The Solventum business, which generated approximately $1 billion of revenue in 2024, is a leading provider of purification and filtration technologies used in biologics production and other applications.

This acquisition is highly complementary to Thermo Fisher's bioproduction business, expanding its capabilities in biologics development and manufacturing. The transaction is expected to be completed by the end of 2025, subject to regulatory approvals. Once closed, Solventum's business will become part of Thermo Fisher's Life Sciences Solutions segment.

The acquisition is expected to generate mid- to high-single digit organic growth and will be dilutive to adjusted EPS by $0.06 in the first year, but accretive by $0.28 excluding financing costs. Thermo Fisher expects to realize approximately $125 million of adjusted operating income from synergies by year five.

Solventum (NYSE: SOLV) announced that its AI-powered radiology speech reporting solution, Fluency for Imaging, has been ranked #1 in the 2025 Best in KLAS Awards for the fifth time. The solution helps radiologists improve efficiency and reduce burnout by streamlining the reporting process through faster, more accurate documentation.

Dr. Charles Q. Li from Allegheny Health Network praised the system's exceptional voice recognition accuracy and reliability, noting its decade-long use at their facility. The KLAS recognition is based on customer feedback collected through confidential interviews and product evaluations over a one-year period, evaluating solutions across six key pillars: value, product, loyalty, relationship, operations, and culture.

Solventum (NYSE: SOLV) has announced it will release its fourth quarter and full year fiscal 2024 financial results on Thursday, February 27, 2025, after U.S. financial markets close. Following the results announcement, the company's management will host a webcast to discuss the quarterly performance and provide guidance for fiscal year 2025. Additionally, Solventum plans to host an Investor Day in March 2025.

The T1D Fund, an impact investment fund focused on type 1 diabetes solutions, has appointed Elizabeth Mily as CEO. Mily brings over 30 years of experience from roles at Bristol Myers Squibb, Goldman Sachs, and Barclays, where she specialized in corporate strategy and business development.

In her new role, Mily will guide the fund's resource deployment and expand strategic partnerships to build an ecosystem for new therapies. She will serve as the fund's lead public ambassador, working to increase awareness and investment in T1D research and innovation.

Prior to joining T1D Fund, Mily served as Executive Vice President of Strategy & Business Development at Bristol Myers Squibb, overseeing company strategy, external innovation, and business development. She currently serves on the Board of Solventum (NYSE: SOLV) and Ampersand Biomedicines.

Solventum (NYSE: SOLV) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. Company executives will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 11:30 a.m. ET in New York, NY. Interested parties can access both live and archived versions of the discussion through the company's investor relations website at investors.solventum.com.